Toni Choueiri, MD
@drchoueiri.bsky.social
Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Kohberg Professor of Medicine, Harvard Medical School
Empowering Oncologists: How far can purpose and passion take you in cancer care? @drchoueiri.bsky.social oncodaily.com/dialogues/31... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EmpoweringOncologists
Empowering Oncologists: How far can purpose and passion take you in cancer care? - OncoDaily
Empowering Oncologists: How far can purpose and passion take you in cancer care? / cancer, Empowering Oncologists, Jasmine Kamboj, OncoDaily, Oncology, Toni
oncodaily.com
In 2023, the @fda.gov approved belzutifan for certain kidney cancers –– thanks to years of work led by Nobel Prize recipient William G. Kaelin Jr., MD. Now, @drchoueiri.bsky.social, director of our Lank Center for Genitourinary Oncology, and team are working to expand its clinical use.
Chain Reaction: The Belzutifan Journey | Dana-Farber Cancer Institute
Basic science discoveries made by Dana-Farber's William G. Kaelin Jr., MD, and his colleagues are propelling powerful new therapies for kidney cancer.
bit.ly
@drchoueiri.bsky.social discusses promising results from the phase 1 ARC-20 study, exploring the combination of Casdatifan and cabozantinib in patients with previously treated clear cell renal cell carcinoma. #ASCO25
1 week left to support @danafarber.bsky.social & Gronk Nation Youth Foundation! Help us finish strong + take on @RobGronkowski! 🎟️ $187+ = ticket to the event 🏈 $100+ = chance to win signed Gronk football 👀 Gronk, Edelman, Ninkovich, Chung 📅 Deadline: May 20 🔗 charity.pledgeit.org/pickleball/t...
Support Kancer Killers - Pickleball for a Purpose 2025
We're excited to join this incredible initiative! This organization's mission is very important to us and we're proud to help them make a difference. Please support us by giving to our page. Every dol...
charity.pledgeit.org
“I can imagine no heroism greater than motherhood." - Happy Mothers day mom and all the mothers in the world ! #HappyMothersDay2025
We’re getting ready to wrap up #AACR25 today, but not before once again congratulating @danafarbernews.bsky.social’s Matthew Meyerson, MD, PhD, FAACR, @drchoueiri.bsky.social and Alice T. Shaw, MD, PhD, for receiving @theaacr.bsky.social 2025 Scientific Achievement Awards. bit.ly/4j7m8om
Thank you @theaacr.bsky.social for the Waun Ki Hong Award! My talk will be addressing Precision Medicine in Renal Cell Carcinoma. See you in Chicago! cc: @danafarber.bsky.social
Our own @danafarber.bsky.social Dr. @NarjustFlorezMD is running for @iaslc.bsky.social Board. Let us support NJ! @narjustflorezmd.bsky.social @danafarbernews.bsky.social
Thank you @theaacr.bsky.social for this honor !
Dana-Farber News@danafarbernews.bsky.social · last yr.Congratulations to @danafarbernews.bsky.social’s Matthew Meyerson, MD, PhD, FAACR, @drchoueiri.bsky.social, and Alice T. Shaw, MD, PhD, recipients of @theaacr.bsky.social 2025 Scientific Achievement Awards. bit.ly/4j7m8om
“Our focused efforts are yielding results that are helping patients today and guiding our research towards more advances in the future,” says @drchoueiri.bsky.social. Learn about the research advancements our Lank Center for Genitourinary Oncology has made this past year.
A Year of Advances in Genitourinary Cancer
Published: February 6, 2025Written by: Beth DoughertyMedically Reviewed By: Atish Choudhury, MD, PhD, Toni Choueiri, MD, and Mark Pomerantz, MDDana-Farber’s genitourinary cancer team is devoted to res...
bit.ly
💬 Transatlantic Exchange : interview croisée du Dr @drchoueiri.bsky.social & du Pr Karim Fizazi. Le 19 mars s’est tenue à Paris la 4e édition des Transatlantic Exchanges, une journée scientifique co-organisée par @gustaveroussy.fr et le @danafarber.bsky.social. ⬇
“It may be that the satisfaction I need depends on my going away, so that when I've gone and come back, I'll find it at home”—Rumi, 13th century
Another year, another #pickeball tournament with our good friend Rob Gronkowski #DaGronk to benefit our Research and Gronk Nation Youth Foundation. Join me and donate at: charity.pledgeit.org/pickleball/@to… #curecancer #beatgronk
This weekend, thanks to the support of the @redsox.com, @danafarber.bsky.social & @thejimmyfund.bsky.social gathered @fenwaypark.bsky.social to celebrate the impact of our Campaign. We celebrated our donors who help us defy Cancer together !
Yesterday, @drchoueiri.bsky.social and Karim Fizazi, MD, PhD, kicked off The Fourth Transatlantic Exchange in Oncology: Radiopharmaceutical Therapy Meets Oncology. Learn more about the collaborative event with @gustaveroussy.fr: bit.ly/42fC69Z
Thank you @TownofWestwood and Lenny Strauss for highlighting our @PanMass journey the past several years, both @mvmombo and I. We are committed @DanaFarber to end Cancer! hometownweekly.net/westwood/dr-ch… Our @CowbellTeam Link for donations to cure Cancer: teammorecowbell.com/
hometownweekly.net
www.globenewswire.com/news-release...
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
– VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful...
globenewswire.com
Happy International Women’s day to the wonderful GU Oncology Women’s @danafarber.bsky.social (front row)
Our new paper in JITC with a group of fine international friends, mentees and colleagues about immunotherapy in patients with cardiac metastasis. jitc.bmj.com/content/13/3/e… @danafarber.bsky.social jitc.bmj.com/content/13/3...64
Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
Background Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited. Methods This is an inte...
jitc.bmj.com
Promising results: Adjuvant neoantigen vaccination prevents recurrence of kidney cancer bit.ly/3EUpSKG @danafarber.bsky.social @braunmdphd.bsky.social @yalecancer.bsky.social @drchoueiri.bsky.social
#GU25 was an outstanding @ascocancer.bsky.social meeting: catching up with friends/ colleagues, watching mentees grow, learn up-to-date GU cancers management, and presenting a new HIF-2 inhibitor (casdatifan) data. Energized! The future is bright! @danafarber.bsky.social @jrgralow.bsky.social
Updated results from the phase 2 LITESPARK-003 study on belzutifan + cabozantinib in advanced ccRCC patients! 📊💡 Key insights into combination therapy and improved outcomes @ascocancer.bsky.social #GU25 @drchoueiri.bsky.social
Great to have @drchoueiri.bsky.social stop by our poster @ascocancer.bsky.social #GU25! Appreciate the insightful discussion and your time.
A customized kidney cancer vaccine made from patients’ tumors looked promising in a small study, @drchoueiri.bsky.social et al report in @nature.com. None of the 9 treated people experienced recurrence. Larger trial of mRNA vaccine underway. www.cancerhealth.com/article/pers...
Personalized Vaccine May Help Prevent Kidney Cancer Recurrence
None of the nine patients who received the vaccine after surgery experienced recurrence over three years.
cancerhealth.com
In @statnews.com: 9 patients w/advanced kidney cancer who received an experimental vaccine tailored to tumors’ specific mutations mounted an immune response & remained cancer-free for 3 years. @drchoueiri.bsky.social of @danafarber.bsky.social explains the early-phase clinical trial. bit.ly/4aNK9xs
Personalized cancer vaccine shows potential in kidney cancer
In a Phase 1 study, nine people with advanced kidney cancer became cancer free after receiving personalized vaccines.
bit.ly
It's an incredible proof-of-principle! Fantastic work led by @drchoueiri.bsky.social Personalised cancer vaccines in the adjuvant setting!! www.nature.com/articles/d41...
A personalized cancer vaccine to prevent the return of high-risk kidney cancer
A phase I clinical trial supports the safety and feasibility of a vaccine to limit disease recurrence in people with kidney cancer.
nature.com
A personalized cancer vaccine to prevent the return of high-risk kidney cancer @nature.com @braunmdphd.bsky.social @drchoueiri.bsky.social www.nature.com/articles/d41... www.nature.com/articles/s41...
A personalized cancer vaccine to prevent the return of high-risk kidney cancer
A phase I clinical trial supports the safety and feasibility of a vaccine to limit disease recurrence in people with kidney cancer.
nature.com
Successful anti-cancer immune responses reported in phase 1 trial of a personalized cancer vaccine for #kidneycancer. Research in Nature led by @drchoueiri.bsky.social #PatrickOtt #CatherineWu #DerinKeskin (all of @danafarber.bsky.social) and David Braun of @yalecancer.bsky.social. bit.ly/3CDIT3n
Cancer vaccine shows promise for patients with stage III and IV kidney cancer | Dana-Farber Cancer Institute
All nine patients treated at Dana-Farber Cancer Institute in a phase 1 trial of a personalized cancer vaccine for patients with stage III or IV kidney cancer with a high risk of recurrence, generated ...
bit.ly
Congrats @drchoueiri.bsky.social! Tremendous translational clinical trial with truly elegant science supporting this concept! Excited for the larger studies ongoing for patients in critical need of curative therapies. @theaacr.bsky.social @helloeacr.bsky.social @ascocancer.bsky.social
Toni Choueiri, MD@drchoueiri.bsky.social · last yr.Our paper in @nature.com is finally published: a prospective trial of a personalized Neoantigen Vaccine in Kidney Cancer www.nature.com/articles/s41... This is teamwork with @danafarber.bsky.social @yalecancer.bsky.social @harvardmed.bsky.social + Wu lab www.nature.com/articles/s41...
